Purpose: To describe results of AFX unibody stent-graft treatment for TransAtlantic Inter-Society Consensus (TASC) D aortoiliac occlusive disease (AIOD) with coexistent abdominal aortic aneurysm (AAA). Methods: A retrospective analysis was conducted of 21 consecutive patients (mean age 73.6±6.4 years; 17 men) with TASC D AIOD plus AAA (diameter >3.5 cm) treated electively using the AFX stent-graft. Common iliac artery (CIA) and external iliac artery (EIA) stenosis or occlusion was reported. Outcome measures were technical and clinical success, improvement in ankle-brachial index (ABI), and improvement in Rutherford category. Immediate and midterm patency, AAA exclusion, major adverse events (MAE), and mortality were also evaluated. Results: After AFX deployment (100% technical success), 18 EIAs required adjunctive stenting (none required in the CIA). One patient required a reintervention for closure device failure. At 30-day follow-up, no death or MAE was recorded. Improvement in ABI was registered in all patients (mean 0.91±0.11), with 100% primary patency. At a mean follow-up of 25.2±11.1 months, primary patency was maintained in all cases. No death or amputation occurred; 2 patients had a myocardial infarction. Improvement in ABI was maintained (0.88±0.13) as well as Rutherford category. Conclusion: This study examined the use of the AFX unibody stent-graft for the treatment of TASC D AIOD with concomitant AAA. The AFX stent-graft appears to be a safe and effective solution for these complex lesions, with low morbidity and mortality.
NorgrenLHiattWRDormandyJAet al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–67.
2.
TASC Steering Committee, JaffMRWhiteCJet al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.
3.
SharafuddinMJHoballahJJKresowikTFet al. Long-term outcome following stent reconstruction of the aortic bifurcation and the role of geometric determinants. Ann Vasc Surg. 2008;22:346–357.
4.
de DonatoGBosiersMSetacciFet al. 24-Month data from the BRAVISSIMO: a large-scale prospective registry on iliac stenting for TASC A & B and TASC C & D lesions. Ann Vasc Surg. 2015;29:738–750.
5.
DijkstraMLGoverdePCHoldenAet al. Initial experience with covered endovascular reconstruction of the aortic bifurcation in conjunction with chimney grafts. J Endovasc Ther. 2017;24:19–24.
6.
MaldonadoTSWestinGGJazaeriOet al. Treatment of aortoiliac occlusive disease with the Endologix AFX unibody endograft. Eur J Vasc Endovasc Surg. 2016;52:64–74.
7.
GrimmeFAGoverdePCVerbruggenPJet al. Editor’s choice-first results of the covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for aortoiliac occlusive disease. Eur J Vasc Endovasc Surg. 2015;50:638–647.
8.
SetacciFSirignanoPCappelliAet al. The wonders of a newly available post-analysis CT software in the hands of vascular surgeons. Eur J Vasc Endovasc Surg. 2012;43:404–406.
9.
SirignanoPSpezialeFCapocciaLet al. Iliac and femoro-popliteal arteries morphological CTA features as determinants of outcome after standard EVAR procedures [published online September 16, 2016]. J Cardiovasc Surg (Torino).
10.
SilingardiRAzzoniIGiulianiEet al. Unibody endografts for abdominal aortic aneurysm repair reduce radiation and nephrotoxic exposure compared with modular endografts. Ann Vasc Surg. 2015;29:751–757.
11.
ChangRWGoodneyPPBaekJHet al. Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. J Vasc Surg. 2008;48:362–367.
12.
ConteMSGeraghtyPJBradburyAWet al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50:1462–1473.
13.
RutherfordRBBakerJDErnstCet al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–538.
14.
DorigoWPiffarettiGBenedettoFet al. A comparison between aortobifemoral bypass and aortoiliac kissing stents in patients with complex aortoiliac obstructive disease. J Vasc Surg. 2017;65:99–107.
15.
IndesJEPfaffMJFarrokhyarFet al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and metaanalysis. J Endovasc Ther. 2013;20:443–455.
16.
BredahlKJensenLPSchroederTVet al. Mortality and complications after aortic bifurcated bypass procedures for chronic aortoiliac occlusive disease. J Vasc Surg. 2015;62:75–82.
SzilagyiDEElliotJPSmithRFet al. A thirty-year survey of the reconstructive surgical treatment of aortoiliac occlusive disease. J Vasc Surg. 1986;3:421–436.
19.
HertzerNRBenaJFKarafaMT.A personal experience with direct reconstruction and extra-anatomic bypass for aortoiliofemoral occlusive disease. J Vasc Surg. 2007;45:527–535.
20.
SabriSSChoudhriAOrgeraGet al. Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. J Vasc Interv Radiol. 2010;21:995–1003.
MwipatayiBPThomasSWongJet al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54:1561–1570.
23.
DanczykRCMitchellELPetersenBDet al. Outcomes of open operation for aortoiliac occlusive disease after failed endovascular therapy. Arch Surg. 2012;147:841–845.
